Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patricia Walker

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 23, 2025
Contraceptive use and pregnancy in cystic fibrosis: Survey findings from 10 cystic fibrosis centersEmily M Godfrey, Amalia Magaret, Andrea Roe, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 11, 2023
Palliative care needs among outpatient adults with cystic fibrosis: Baseline data from the Improving Life with CF trialStephanie DiFiglia, Anna M Georgiopoulos, Russell Portenoy, et al.
Journal of Patient Experience|March 20, 2023
Development of a Cystic Fibrosis Primary Palliative Care Intervention: Qualitative Analysis of Patient and Family Caregiver PreferencesMelissa J Basile, Lara Dhingra, Stephanie DiFiglia, et al.
Internal Medicine Journal|July 25, 2022
Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer CentreConstantine S Tam, Gareth P Gregory, Matthew Ku, et al.
Haematologica|October 15, 2020
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletionConstantine S Tam, Tadeusz Robak, Paolo Ghia, et al.
Blood Advances|September 8, 2023
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA studyStephen Opat, Alessandra Tedeschi, Bei Hu, et al.
Leukemia|December 3, 2024
Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemiaJeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.
Leukemia|January 2, 2022
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemiaJeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.
Lancet (London, England)|April 20, 2020
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trialJeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2021
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone LymphomaStephen Opat, Alessandra Tedeschi, Kim Linton, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 23, 2025
Contraceptive use and pregnancy in cystic fibrosis: Survey findings from 10 cystic fibrosis centersEmily M Godfrey, Amalia Magaret, Andrea Roe, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 11, 2023
Palliative care needs among outpatient adults with cystic fibrosis: Baseline data from the Improving Life with CF trialStephanie DiFiglia, Anna M Georgiopoulos, Russell Portenoy, et al.
Journal of Patient Experience|March 20, 2023
Development of a Cystic Fibrosis Primary Palliative Care Intervention: Qualitative Analysis of Patient and Family Caregiver PreferencesMelissa J Basile, Lara Dhingra, Stephanie DiFiglia, et al.
Internal Medicine Journal|July 25, 2022
Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer CentreConstantine S Tam, Gareth P Gregory, Matthew Ku, et al.
Haematologica|October 15, 2020
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletionConstantine S Tam, Tadeusz Robak, Paolo Ghia, et al.
Blood Advances|September 8, 2023
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA studyStephen Opat, Alessandra Tedeschi, Bei Hu, et al.
Leukemia|December 3, 2024
Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemiaJeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.
Leukemia|January 2, 2022
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemiaJeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.
Lancet (London, England)|April 20, 2020
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trialJeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2021
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone LymphomaStephen Opat, Alessandra Tedeschi, Kim Linton, et al.
Pageof 8